Skip to main content
. Author manuscript; available in PMC: 2017 Aug 11.
Published in final edited form as: Melanoma Res. 2016 Jun;26(3):272–277. doi: 10.1097/CMR.0000000000000234

Figure 4.

Figure 4

Heterogeneous In111 octreotide pre-treatment uptake in a patient with metastatic uveal melanoma. (A) Pelvic metastasis with In111 octreotide avidity. (B) Left perinephric metastasis (arrow) without In111 octreotide avidity (with adjacent normal avid spleen visible).